Uniqure NV
NASDAQ:QURE

Watchlist Manager
Uniqure NV Logo
Uniqure NV
NASDAQ:QURE
Watchlist
Price: 5.78 USD -1.11% Market Closed
Market Cap: 281.7m USD
Have any thoughts about
Uniqure NV?
Write Note

Uniqure NV
Deferred Income Tax

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Uniqure NV
Deferred Income Tax Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Deferred Income Tax CAGR 3Y CAGR 5Y CAGR 10Y
Uniqure NV
NASDAQ:QURE
Deferred Income Tax
$7.6m
CAGR 3-Years
-16%
CAGR 5-Years
N/A
CAGR 10-Years
16%
Pharming Group NV
AEX:PHARM
Deferred Income Tax
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
ProQR Therapeutics NV
NASDAQ:PRQR
Deferred Income Tax
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
argenx SE
XBRU:ARGX
Deferred Income Tax
$5m
CAGR 3-Years
-26%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Merus NV
NASDAQ:MRUS
Deferred Income Tax
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
LAVA Therapeutics NV
NASDAQ:LVTX
Deferred Income Tax
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Uniqure NV
Glance View

Market Cap
281.7m USD
Industry
Biotechnology

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. The company is headquartered in Amsterdam, Noord-Holland and currently employs 463 full-time employees. The company went IPO on 2014-02-05. The company seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. The company develops, both internally and through partnerships, a pipeline of gene therapies. The company produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.

QURE Intrinsic Value
11.95 USD
Undervaluation 52%
Intrinsic Value
Price

See Also

What is Uniqure NV's Deferred Income Tax?
Deferred Income Tax
7.6m USD

Based on the financial report for Sep 30, 2024, Uniqure NV's Deferred Income Tax amounts to 7.6m USD.

What is Uniqure NV's Deferred Income Tax growth rate?
Deferred Income Tax CAGR 10Y
16%

Over the last year, the Deferred Income Tax growth was 55%. The average annual Deferred Income Tax growth rates for Uniqure NV have been -16% over the past three years , and 16% over the past ten years .

Back to Top